» Articles » PMID: 28484722

Bacteriophages and Their Immunological Applications Against Infectious Threats

Overview
Journal J Immunol Res
Publisher Wiley
Date 2017 May 10
PMID 28484722
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteriophage therapy dates back almost a century, but the discovery of antibiotics led to a rapid decline in the interests and investments within this field of research. Recently, the novel threat of multidrug-resistant bacteria highlighted the alarming drop in research and development of new antibiotics: 16 molecules were discovered during 1983-87, 10 new therapeutics during the nineties, and only 5 between 2003 and 2007. Phages are therefore being reconsidered as alternative therapeutics. Phage display technique has proved to be extremely promising for the identification of effective antibodies directed against pathogens, as well as for vaccine development. At the same time, conventional phage therapy uses lytic bacteriophages for treatment of infections and recent clinical trials have shown great potential. Moreover, several other approaches have been developed in vitro and in vivo using phage-derived proteins as antibacterial agents. Finally, their use has also been widely considered for public health surveillance, as biosensor phages can be used to detect food and water contaminations and prevent bacterial epidemics. These novel approaches strongly promote the idea that phages and their proteins can be exploited as an effective weapon in the near future, especially in a world which is on the brink of a "postantibiotic era."

Citing Articles

Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.

Abdel-Razek M, Nazeih S, Yousef N, Askoura M AMB Express. 2025; 15(1):37.

PMID: 40044971 PMC: 11882492. DOI: 10.1186/s13568-025-01846-0.


T4 Phage Displaying Dual Antigen Clusters Against H3N2 Influenza Virus Infection.

Liu S, Lin M, Zhou X Vaccines (Basel). 2025; 13(1).

PMID: 39852849 PMC: 11769387. DOI: 10.3390/vaccines13010070.


Emerging roles of bacteriophage-based therapeutics in combating antibiotic resistance.

Subramanian A Front Microbiol. 2024; 15:1384164.

PMID: 39035437 PMC: 11257900. DOI: 10.3389/fmicb.2024.1384164.


Phage therapy: breathing new tactics into lower respiratory tract infection treatments.

Vaezi A, Healy T, Ebrahimi G, Rezvankhah S, Hashemi Shahraki A, Mirsaeidi M Eur Respir Rev. 2024; 33(172).

PMID: 38925791 PMC: 11216685. DOI: 10.1183/16000617.0029-2024.


Exploring the Bacteriophage Frontier: A Bibliometric Analysis of Clinical Trials Between 1965 and 2024.

Dagli N, Haque M, Kumar S Cureus. 2024; 16(3):e56266.

PMID: 38495963 PMC: 10943599. DOI: 10.7759/cureus.56266.


References
1.
Gu J, Zuo J, Lei L, Zhao H, Sun C, Feng X . LysGH15 reduces the inflammation caused by lethal methicillin-resistant Staphylococcus aureus infection in mice. Bioeng Bugs. 2011; 2(2):96-9. DOI: 10.4161/bbug.2.2.14883. View

2.
Schmelcher M, Donovan D, Loessner M . Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012; 7(10):1147-71. PMC: 3563964. DOI: 10.2217/fmb.12.97. View

3.
Olson N, Morrow J . DNA extract characterization process for microbial detection methods development and validation. BMC Res Notes. 2012; 5:668. PMC: 3599793. DOI: 10.1186/1756-0500-5-668. View

4.
Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A . Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. mBio. 2014; 5(4):e01379-14. PMC: 4161244. DOI: 10.1128/mBio.01379-14. View

5.
Oechslin F, Daraspe J, Giddey M, Moreillon P, Resch G . In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia. Antimicrob Agents Chemother. 2013; 57(12):6276-83. PMC: 3837886. DOI: 10.1128/AAC.01701-13. View